Figure 1.
Reduction in the odds of testing positive for SARS-CoV-2 (left panel) and in having a positive test with symptoms (right panel) among individuals who had received 1 or 2 doses of BNT162b2 vaccine compared to unvaccinated adolescents, by time since vaccination. In red, vaccine effectiveness against SARS-CoV-2 infection, and in blue, against symptomatic infection. Vertical bars represent 95% confidence intervals. Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
